Adipocytes Xagena










Year: 2010 2009 2008 2007 All

Adipocytes

News

Page 1 of 1

Risk of psychiatric side effects is approximately doubled in patients taking Acomplia: The European Medicines Agency ( EMEA ) has completed a review of Acomplia ( Rimonabant ) at the request of the European Commission, following concerns over the medicine�s psychiatric safety. The Agency�s Committee for Medicinal Products for Human Use ( CHMP ) has concluded that the benefits of Aco...
Read Article

Rimonabant: safety issues: Rimonabant ( Acomplia / Zimulti ) is a cannabinoid receptor antagonist. It acts by blocking a specific type of receptor called cannabinoid type 1 ( CB1 ) receptors. These receptors are found in the nervous system and are part of the system that the body uses to control food intake. By blocking the r...
Read Article

Rosiglitazone associated with parotid gland enlargement: The thiazolidinedione Rosiglitazone ( Avandia ) is an insulin sensitizer that is indicated for use either as monotherapy or in combination with Metformin or a sulfonylurea in patients whose type 2 diabetes is inadequately controlled by diet and exercise alone. In the January 2006 issue of the Can...
Read Article

Rimonabant, a new drug for weight loss: Rimonabant ( Acomplia ) is an oral selective cannabinoid CB1 receptor antagonist. It is licensed as an adjunct to diet and exercise for the treatment of obese patients( BMI >30Kg/m2 ), or overweight patients ( BMI >27Kg/m2 ) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia. ...
Read Article

Chlamydia trachomatis escapes recognition by the host by cloaking itself in fat-rich structures: The Chlamydiae learned to parasitize eukaryotic cells half a billion years ago by reprogramming cellular functions from within. In humans today, chlamydial infections are responsible for a range of ailments from sexually transmitted infections to atypical pneumonias to chronic severe disorders such...
Read Article

Insulin's role in blocking release of energy in patients with type II diabetes: Researchers at the University of California, San Diego ( UCSD ) School of Medicine discovered that chronically high levels of insulin, as is found in many people with obesity and type II diabetes, may block specific hormones that trigger energy release into the body. The findings are published in...
Read Article

Defective lymphatic vessels identified as a novel cause of adult-onset obesity: Laboratory model missing one copy of Prox1 gene exhibits abnormal increase in fat accumulation around sites of lymph leakage from defective lymphatic vessels. Leaky lymphatic vessels are the leading cause of the adult onset obesity observed in a laboratory model developed by investigators at St. ...
Read Article

A switch allows preadipocytes to form fat cells: Researchers, at University of Michigan Life Sciences Institute, found that a hormonal cocktail routinely used in the lab induces a key genetic switch in the transition from fat-cell precursors to full-blown fat. " The body needs fat cells, both as a storage depot for fuel and as cells that sense ...
Read Article

Pages:1

Farmaci

Home

Farmacovigilanza

Progetto Farmaci